AACR 2026 年会

2026 年 4 月 17–22 日 · San Diego · 共 2429 条

← ADC 下一代 — 载荷创新

HER2

临床试验

11 人 · 11 条 · 8 篇摘要

本事件热度走势

当前热度 1·可比范围峰值 2（4月22日 11:00）·近 24 小时可比范围变化 –·当前参与者 3

参与者计数3

热度走势

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。

记录

药 / 试验	读数	场景
T-DXd + pertuzumabtrastuzumab HER2 #BREASTCANCER	PFS HR 0.56（40.7 vs 26.9 月）	DESTINY-Breast09 · 1L HER2+ mBC · Ph3
zanidatamab 新辅助zanidatamab HER2	无化疗 pCR 30%，HER2 下调 56%	NeoZanHER · 早期 HER2+++

载荷创新是这一届 ADC 的 field-level 方向，不是又开一条赛道。T-DXd 已经在改一线标准；DAC 的临床还薄——Prelude 的 SMARCA2 降解剂单药缓解大约 15%，要从概念走到能卖，数字还差一截。

其他对照

olaparib + T-DXd确认缓解 42.9%，mDOR 11.2 月（n=28）
risvutatugB7-H3 ADC，会场 ORR 约 47%
AVA6103 / pan-RAS ADCtricomplex pan-RAS 作 payload

zanidatamab 同时绑 HER2 的两个结构域（曲妥珠和帕妥珠各绑一个），不靠化疗的细胞毒。T-DXd 是另一极：用 ADC 的载荷把一线标准往上推，代价是间质性肺病。

记录

药 / 试验	读数	场景
T-DXd + pertuzumabtrastuzumab HER2 #BREASTCANCER	PFS HR 0.56；ILD 约 12%，含 2 例 5 级	DESTINY-Breast09 · 1L HER2+

HER2 一线正在被 ADC 改写，de-escalation 是另一条更窄的路：少打化疗、毒性下来，但 pCR 30% 撑不起大 III 期。两条路不要混成「乳腺癌都在涨」。

其他对照

zanidatamab无化疗新辅助 pCR 30%
pumitamigTNBC cORR 61.5%
NSABP-B-59ctDNA 预测非 pCR 与远处复发

证据

4461

Nebivolol exhibits cell growth inhibition in drug-resistant HR+/HER2- breast cancer and anti-tumoral synergism with abemaciclib

Chia-Ling Wu, Meghana Trivedi, Shivaani Suresh Kanna

读摘要原文 →

6741

Tertiary lymphoid structure (TLS)-associated immune circuits define response to durvalumab, trastuzumab, and pertuzumab (DTP) in HER2-enriched early breast cancer

Mailin Li, Xen Ping Hoi, Jenying Deng, Junjun Zheng, Rabia Hashmani, Recep Bayraktar, Wei Qian, Jianying Zhou, Jian Guan, Kai Sun, Hanh Mai, Tiffany Sheu, Susan Haley, Mary Schwartz, Sunil Mathur, Stephen T. Wong, Fotis Nikolo, Keith Syson Chan, Polly Niravath, Jenny C. Chang

读摘要原文 →

CT011

Genomic HER2 amplification predicts for complete clinical response in a phase II study of induction tucatinib and trastuzumab combined with chemotherapy in locally advanced rectal adenocarcinoma

Michael B. Foote, Jinru Shia, Callahan Wilde, Marinela Capanu, Joanne Chou, Vetri Sudar Jayaprakasam, Marc Gollub, Miteshkumar Patel, Mina Ito, Leonard B. Saltz, Devika Rao, Neil Segal, Maliha Nusrat, Karuna Ganesh, Paul Romesser, Julio Garcia-Aguilar, Martin Weiser, Rona Yaeger, Luis A. Diaz, Andrea Cercek

读摘要原文 →

CT012

A phase 2 single-arm open-label trial evaluating zanidatamab in patients with early stage HER2 positive breast cancer: The NeoZanHER Study

Vicente Valero, Paula R. Pohlmann, Jason Mouabbi, Xuelin Huang, Wei Qiao, Heather R. Alonzo, Rashmi Krishna Murthy, Gaiane M. Rauch, Taiwo Adesoye, Cristina M. Checka, William F. Symmans, Dmitri Grachev, Flora Alajajyan, Adaeze Nwosu-Iheme, Amy Hassan, Miral Mahesh Patel, Sharon H. Giordano, Kelly Hunt, Debasish Tripathy, Funda Meric-Bernstam

读摘要原文 →

CT035NCT04585958

CTEP #10355 A phase 1 trial of DS-8201a and olaparib in HER2-expressing malignancies: Results from dose escalation

Elizabeth K. Lee, Andrea Wahner Hendrickson, Gerardo Colon-Otero, Cheryl A. Pickett, Yinglu Zhou, Su-Chun Cheng, Madeline Polak, Hannah Sawyer, Martin Hayes, Ursula A. Matulonis, Geoffrey I. Shapiro, Panagiotis A. Konstantinopoulos

读摘要原文 →

CT045

Initial clinical and translational results and selection of recommended phase 2 dose (RP2D) from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in metastatic triple-negative or HR+/HER2- breast cancer

Steven J Isakoff, Anastasia Martynova, Philippe L Bedard, Margaret E Gatti-Mays, Nathalie LeVasseur, Andreas Varkaris, William Randolph, Karunya Srinivasan, Shannon McCue, Zhenming Shun, Ke Liu, Zhen Su, Kevin Chin, Virginia Kaklamani, Kelly McCann, Erika Hamilton

读摘要原文 →

CT262

Elacestrant (Ela) in combination with everolimus (Eve) or abemaciclib (Abema) in patients with ER+/HER2- locally advanced or metastatic breast cancer mBC: phase 2 results from ELEVATE, an open-label, umbrella study

Hope S. Rugo, Sara M. Tolaney, Nancy Chan, Giuliano Borges, Rinat Yerushalmi, Marina N. Sharifi, Wassim McHayleh, Thaddeus Beck, Neelima Vidula, Erika Hamilton, Kristine J. Rinn, Joyce O’Shaughnessy, Giuseppe Curigliano, Javier Cortés, Paula Muñoz Romero, Giulia Tonini, Alessandro Paoli, Monica Binaschi, Li Cheng, Jennifer A. Crozier, Tomer Wasserman, Virginia Kaklamani

读摘要原文 →

CT275NCT07151586

ALTER: A randomized Phase II trial evaluating an upfront alternating regimen of sacituzumab-govitecan and trastuzumab-deruxtecan versus sacituzumab-govitecan alone in HER2-low metastatic triple-negative breast cancer (NCT07151586)

Alexandre de Nonneville, Jean-Marie Boher, Jean-Sébastien Frenel, Gerald Bagoe, Olivier Tredan, Marie-Ange Mouret-Reynier, Chayma Bousrih, Vincent Massard, Julien Grenier, Marie Robert, Florence Lerebours, Delphine Loriat, Florence Dalenc, Christelle Jouannaud, Stéphanie Becourt, Philippe Follana, Sylvain Ladoire, William Jacot, Bogdan-Valentin Popescu, Maxime Brunet, George Emile, Jerôme Lemmonier, Sylvie Mijonnet, Anthony Gonçalves, François Bertucci

读摘要原文 →

现场

今天10月23日周五

星期五 · 2 条